Aurinia Pharmaceuticals AUPH Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Rogers CorporationROG

$20.6M-13.1%

Opko HealthOPK

$44.99M-4.7%

LQD

Liquidia CorporationLQDA

$6.96M+1.5%

Mirum Pharmaceuticals, Inc.MIRM

$12.87M+29.2%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

BridgeBio PharmaBBIO

$18.66M+84.3%

FAQ

What is Aurinia Pharmaceuticals's operating lease liabilities (total)?

Aurinia Pharmaceuticals (AUPH) reported operating lease liabilities (total) of $3.71M in Q2 2026.

How has Aurinia Pharmaceuticals's operating lease liabilities (total) changed year-over-year?

Aurinia Pharmaceuticals's operating lease liabilities (total) decreased by 41.8% year-over-year, from $6.38M to $3.71M.

What is the long-term trend for Aurinia Pharmaceuticals's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's operating lease liabilities (total) has grown at a -6.6% compound annual growth rate (CAGR), from $8.41M to $5.97M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.